GREENVILLE, S.C.--(EON: Enhanced Online News)--SCRA Technology Ventures’ SC Launch today announced that Portfolio Company, KIYATEC, has received a National Cancer Institute Phase I SBIR (Small Business Innovation Research) contract. The $295,000 award will be used to establish three dimensional breast cancer models using living cells obtained directly from breast cancer patients. The models will then be used to screen anticancer drugs during pre-clinical development and to test patient-derived samples in real time to assist clinical decision making. The National Cancer Institute is one of the 27 institutes and centers that comprise the National Institutes of Health.
“We would like to congratulate KITAYEC on their most recent achievement”
"We are very grateful for this award from the National Cancer Institute through the SBIR program to advance KIYATEC's development of predictive 3D cell-based cancer models, and are proud to be collaborating on an initiative that can potentially bring benefit to the millions of American women who have or will be diagnosed with breast cancer," said Dr. Matt Gevaert, KIYATEC’s CEO. "This contract’s focus on breast cancer builds on our existing body of work across multiple solid tumor types, including ovarian cancer. Demonstrating this breadth of applicability is important as we engage pharmaceutical and biotechnology companies to leverage KIYATEC’s assays to help them better predict human patient response before, during and after clinical trials. This contract will aid us in doing so and we expect it will catalyze further exciting and meaningful ex vivo cancer assay development."
“We would like to congratulate KITAYEC on their most recent achievement,” said SCRA CEO Bill Mahoney. “Our award-winning, internationally recognized SC Launch program continues to help companies, like KIYATEC, grow and succeed, while strengthening South Carolina’s Knowledge Economy. We look forward to KIYATEC’s future accomplishments.”
As a result of a competitive process, KIYATEC has also been selected as a main stage presenter at the 15th Anniversary Southeast BIO Investor & Partnering Forum. The event is the Southeast region's premier life sciences and medical technology conference, connecting emerging companies with potential investors and partners in a forum that provides meaningful networking opportunities. SCRA Technology Ventures will attend and present an award at the event, which will take place from November 5-7 in Richmond, Virginia at the Jefferson Hotel.
The contract is being funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201300043C.
About SCRA Technology Ventures
SCRA Technology Ventures helps innovative companies grow and develop new technologies, creating jobs and advancing the Knowledge Economy throughout South Carolina. This SCRA business sector provides support and mentoring through its flagship SC Launch program to early stage, start-up technology companies. Since 2006, SCRA has deployed over $72 million in funding and infrastructure to support over 280 high-tech, early-stage enterprises, and has directly invested nearly $16 million in South Carolina start-ups, attracting over $250 million in private investment. SCRA Technology Ventures also supports commercialization and growth by facilitating the transfer of intellectual property and accelerating the transition of inventions to the marketplace. Additionally, SCRA Technology Ventures invests in more established technology companies through its Stage 2 affiliate.
Multiple economic impact studies show SCRA's cumulative output on South Carolina's economy to be over $15.3 billion, and that the company has helped create approximately 15,000 technology-related jobs in the state, with annual wages averaging between $55,000 and $77,000.
About KIYATEC Inc.
KIYATEC specializes in providing advanced, 3D cell-based assays and diagnostics with superior physiologic relevance for more accurate ex vivo prediction of patient response to drugs. KIYATEC’s Greenville, South Carolina offices and labs are co-located with the Institute for Translational Oncology Research (ITOR) Clinical Research Unit on the main campus of the Greenville Health System, the 13th largest public hospital system in the United States. We utilize primary sourced cells and tissues, immunoassays, imaging and other analytical capabilities to provide valuable data and insight to meet the needs of the pharmaceutical, biotechnology and healthcare industries. KIYATEC is also developing robust phenotypic cell-based cancer diagnostics using viable tumor biopsies to assess patient-specific response to available therapeutic agents.
By leveraging KIYATEC’s specialized expertise and clinical connectivity, we add significant value to our clients’ preclinical, adaptive or co-clinical trials, and post-approval small molecule and biologic programs. Our technologies and methods provide more accurate simulation of phenomenon inherent within the living systems of the human body. Accurate modeling of these dynamic conditions creates opportunity for enhanced diagnostics and advanced medical treatments that will benefit society through the resulting improvements in healthcare and its associated costs.